Properties | Information | |
---|---|---|
PhytoCAT-ID | PhytoCAT-1085 | |
Phytochemical name or plant extracts | Kahweol | |
PMID | 30205135 | |
Literature evidence | Kahweol treatment substantially reduced the levels of HER2 protein, mRNA, and transcriptional activity in SKBR3 cells. | |
IUPAC name | (1S,4S,12S,13R,16R,17R)-17-(hydroxymethyl)-12-methyl-8-oxapentacyclo[14.2.1.01,13.04,12.05,9]nonadeca-5(9),6,10-trien-17-ol | |
Phytochemicals’ class or type of plant extracts | Diterpenoid | |
Source of phytochemicals or plant Extracts | Coffea arabica | |
Geographical availability | Ethiopia, Kenya, Sudan | |
Plant parts | Beans | |
Other cancers | Breast cancer | |
Target gene or protein | PEA3, AP-2, FASN, SREBP-1c, mTOR | |
Gene or Protein evidence | Kahweol exerts its potent anticancer efficacy by the upregulation of polyomavirus enhancer activator 3 (PEA3) and downregulation of activator protein 2 (AP-2) to inhibit aberrantly activated HER2 signaling. Fatty acid synthase (FASN) expression and sterol regulatory element-binding protein-1c (SREBP-1c) activity were downregulated by kahweol. In addition, kahweol lowered the levels of phosphorylated Akt and its downstream targets mammalian target of rapamycin (mTOR) and cyclin D1. | |
Target pathways | Kahweol preferentially inhibited cell proliferation and induced cell death through the induction of a caspase 3-dependent pathway in HER2-overexpression breast cancer cell lines. | |
IC50 | NA | |
Potency | Overall, this study suggests that kahweol could be a useful adjuvant therapeutic agent in the treatment of HER2-overexpressing breast cancer. | |
Cell line/ mice model | SKBR-3 | |
Additional information | Furthermore, we found that blocking Akt signaling through kahweol treatment significantly reduced FASN expression and subsequently suppressed cell proliferation in HER2-overexpressing cancer cells. | |
PubChem ID | 114778 | |
Additional PMIDs | NA | |
Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:747038-1 | |
Safety | NA |